» Articles » PMID: 29774530

Programmed Necrosis in Cardiomyocytes: Mitochondria, Death Receptors and Beyond

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2018 May 19
PMID 29774530
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Excessive death of cardiac myocytes leads to many cardiac diseases, including myocardial infarction, arrhythmia, heart failure and sudden cardiac death. For the last several decades, most work on cell death has focused on apoptosis, which is generally considered as the only form of regulated cell death, whereas necrosis has been regarded to be an unregulated process. Recent findings reveal that necrosis also occurs in a regulated manner and that it is closely related to the physiology and pathophysiology of many organs, including the heart. The recognition of necrosis as a regulated process mandates a re-examination of cell death in the heart together with the mechanisms and therapy of cardiac diseases. In this study, we summarize the regulatory mechanisms of the programmed necrosis of cardiomyocytes, that is, the intrinsic (mitochondrial) and extrinsic (death receptor) pathways. Furthermore, the role of this programmed necrosis in various heart diseases is also delineated. Finally, we describe the currently known pharmacological inhibitors of several of the key regulatory molecules of regulated cell necrosis and the opportunities for their therapeutic use in cardiac disease. We intend to systemically summarize the recent progresses in the regulation and pathological significance of programmed cardiomyocyte necrosis along with its potential therapeutic applications to cardiac diseases. LINKED ARTICLES: This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc.

Citing Articles

The Cardiomyocyte in Cirrhosis: Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy.

Ryu D, Yu F, Yoon K, Liu H, Lee S Rev Cardiovasc Med. 2025; 25(12):457.

PMID: 39742234 PMC: 11683693. DOI: 10.31083/j.rcm2512457.


Mechanistic elucidation of ferroptosis and ferritinophagy: implications for advancing our understanding of arthritis.

Guo C, Peng J, Cheng P, Yang C, Gong S, Zhang L Front Physiol. 2024; 15:1290234.

PMID: 39022306 PMC: 11251907. DOI: 10.3389/fphys.2024.1290234.


Trafficking and effect of released DNA on cGAS-STING signaling pathway and cardiovascular disease.

Zhou Z, Ou-Yang C, Chen Q, Ren Z, Guo X, Lei M Front Immunol. 2023; 14:1287130.

PMID: 38152400 PMC: 10751357. DOI: 10.3389/fimmu.2023.1287130.


RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications.

Ke D, Zhang Z, Liu J, Chen P, Dai Y, Sun X Front Immunol. 2023; 14:1274654.

PMID: 37954576 PMC: 10639174. DOI: 10.3389/fimmu.2023.1274654.


Liraglutide Attenuates Myocardial Ischemia/Reperfusion Injury Through the Inhibition of Necroptosis by Activating GLP-1R/PI3K/Akt Pathway.

Zhou G, Wu H, Yang J, Ye M, Liu D, Li Y Cardiovasc Toxicol. 2023; 23(3-4):161-175.

PMID: 36934206 DOI: 10.1007/s12012-023-09789-3.


References
1.
Orogo A, Gustafsson A . Cell death in the myocardium: my heart won't go on. IUBMB Life. 2013; 65(8):651-6. PMC: 4074399. DOI: 10.1002/iub.1180. View

2.
Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway J . Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012; 3:e437. PMC: 3542611. DOI: 10.1038/cddis.2012.176. View

3.
Konstantinidis K, Whelan R, Kitsis R . Mechanisms of cell death in heart disease. Arterioscler Thromb Vasc Biol. 2012; 32(7):1552-62. PMC: 3835661. DOI: 10.1161/ATVBAHA.111.224915. View

4.
Keogh A . Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant. 2004; 23(5 Suppl):S202-6. DOI: 10.1016/j.healun.2004.03.008. View

5.
Alexander S, Cidlowski J, Kelly E, Marrion N, Peters J, Faccenda E . THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors. Br J Pharmacol. 2017; 174 Suppl 1:S208-S224. PMC: 5650662. DOI: 10.1111/bph.13880. View